• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Tvardi Therapeutics, Inc. - Common Stock (NQ:TVRD)

    3.380 -0.420 (-11.05%)
    Streaming Delayed Price Updated: 2:01 PM EDT, Jul 10, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Headline News about Tvardi Therapeutics, Inc. - Common Stock

    Which stocks are experiencing notable movement on Thursday? ↗
    Via Chartmill
    On Thursday, there are stocks with unusual volume. Let's take a look. ↗
    Via Chartmill
    Wondering what's happening in today's after-hours session? ↗
    Via Chartmill
    Here are the top movers in Wednesday's session. ↗
    Via Chartmill
    News headline image
    12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
    Gainers Catheter Precision (AMEX:VTAK) shares moved upwards by 95.7% to $1.4 during Wednesday's regular session. The market value of their outstanding shares is at $2.5 million. Tvardi Therapeutics... 
    Via Benzinga
    The trading volume of these stocks is deviating from the norm in today's session. ↗
    Via Chartmill
    Let's take a look at the stocks that are in motion in today's session. ↗
    Via Chartmill
    Let's have a look at the top gainers and losers one hour before the close of the markets of today's session. ↗
    Via Chartmill
    News headline image
    12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
    Gainers Crinetics Pharmaceuticals (NASDAQ:CRNX) shares moved upwards by 98.7% to $83.53 during Tuesday's regular session. The company's market cap stands at $4.4 billion. Tvardi Therapeutics... 
    Via Benzinga
    Top stock movements in today's session. ↗
    Via Chartmill
    The trading volume of these stocks is deviating from the norm in today's session. ↗
    Via Chartmill
    Get insights into the top gainers and losers of Wednesday's pre-market session. ↗
    Via Chartmill
    News headline image
    Unusual volume stocks in Monday's session ↗
    In today's session, these stocks are experiencing unusual volume. 
    Via Chartmill
    News headline image
    In today's session, these stocks are experiencing unusual volume. ↗
    Unusual volume stocks are being observed in Thursday's session. 
    Via Chartmill
    News headline image
    Unusual volume stocks in Wednesday's session ↗
    Which stocks have an unusual volume on Wednesday? 
    Via Chartmill
    News headline image
    12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
     
    Via Benzinga
    News headline image
    Tvardi Therapeutics' Lung Disease Candidate Fails To Show Any Clinical Benefit, Stock Sinks ↗
    Tvardi Therapeutics stock falls as Phase 2 IPF trial of TTI-101 shows no significant FVC improvement, with high variability and placebo response. 
    Via Benzinga
    News headline image
    Gold Rises Over 3%; Tvardi Therapeutics Shares Plunge ↗
     
    Via Benzinga
    News headline image
    12 Health Care Stocks Moving In Monday's Intraday Session ↗
     
    Via Benzinga
    News headline image
    Dow Surges 1%; Fastenal Shares Fall After Q3 Results ↗
     
    Via Benzinga
    Topics Stocks
    News headline image
    12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
     
    Via Benzinga
    News headline image
    Why Did Tvardi Therapeutics Stock Plummet 87% Pre-Market Today? ↗
    The company said that its investigational drug did not meet its goal in a study, and no statistically significant differences between placebo and treatment arms were observed after preliminary review... 
    Via Stocktwits
    News headline image
    Tvardi Posts Q2 Net Income Turnaround ↗
    Via The Motley Fool
    Topics Intellectual Property
    News headline image
    Recently Listed Tvardi Therapeutics' Lead Drug 'Positioned To Drive Broad Improvement', Analyst Sees Over 150% Stock Upside ↗
    Tvardi advances fibrosis drug TTI-101 in IPF and liver cancer as Piper initiates with $78 target; merger boosts cash runway into late 2026. 
    Via Benzinga
    News headline image
    This Modine Manufacturing Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday ↗
     
    Via Benzinga
    News headline image
    12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
     
    Via Benzinga
    News headline image
    12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
     
    Via Benzinga
    News headline image
    Why Coursera Shares Are Trading Higher By Over 7%; Here Are 20 Stocks Moving Premarket ↗
     
    Via Benzinga
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.